Provectus Pharmaceuticals, Inc. a development-stage oncology and dermatology biopharmaceutical company, announces the Company has formed an independent board to meet corporate governance requirements like that of NASDAQ, which requires a majority of independent Board Members. To accomplish this, Jan E. Koe has been appointed to its Board of Directors and Eric Wachter, Ph.D., has resigned from the Board and named Chief Technology Officer, a new position.
More Info:
www.businesswire.com/news/home/20120514005283/en/Provectus-Pharmaceuticals-Forms-Independent-Board-Meet-Corporate
More Info:
www.businesswire.com/news/home/20120514005283/en/Provectus-Pharmaceuticals-Forms-Independent-Board-Meet-Corporate
No comments:
Post a Comment